Copyright
©The Author(s) 2023.
World J Gastrointest Endosc. Jun 16, 2023; 15(6): 440-446
Published online Jun 16, 2023. doi: 10.4253/wjge.v15.i6.440
Published online Jun 16, 2023. doi: 10.4253/wjge.v15.i6.440
Ref. | No. of patients | Etiology | Location | ID-RFA catheter | ID-RFA setting | Stent type | No. of ID-RFA applications | Stent patency period (median/mean) | Survival period (median/mean) | Adverse event rate | |||||||
RFA + stent | Stent | ID-RFA + stent | Stent | P value | ID-RFA + stent | Stent | P value | ID-RFA + stent | Stent | P value | |||||||
Yang et al[9], 2018 | 32 | 33 | Cholangiocarcinoma | Distal, hilar | Habib | 7-10W; 90s | PS | Every 3 ma | 6.8 mb | 3.4 mb | 0.02 | 13.2 m | 8.3 m | < 0.001 | 6.3% | 9.1% | 0.67 |
Kang et al[10], 2021c | 24 | 24 | Cholangiocarcinoma, pancreatic cancer, other | Distal, Hilar | ELRA | 7W/10W; 120s; 80℃ | UMS | 1 | 132 d | 116 d | 0.440 | 244 m | 180 m | 0.281 | 4.2% | 12.5% | 0.609 |
Gao et al[11], 2021 | 87 | 87 | Cholangiocarcinome | Distal, hilar | Habib | 7-10W; 90s | PS | 2 | 3.7 m | 4.1 m | 0.674 | 14.3 m | 9.2 m | < 0.001 | 27.6% (early event) | 19.5% (early event) | 0.211 |
Kang et al[12], 2022 | 15 | 15 | Cholangiocarcinoma, gallbladder cancer | Hilar | ELRA | 7W; 60-120s; 80℃ | UMS | 1-2 | 178 d | 122 d | 0.154 | 230 d | 144 d | 0.643 | NA | NA | NS |
Albers et al[13], 2022 | 42 | 44 | Cholangiocarcinoma, pancreatic cancer, other | Distal, Hilar | Habib | 10W; 90s | UMS | 1 | NAd | NAd | NAd | NAd | NAd | NAd | 10.5% | 2.3% | P = 0.18 |
- Citation: Inoue T, Yoneda M. Endoscopic intraductal radiofrequency ablation for extrahepatic cholangiocarcinoma: An update (2023). World J Gastrointest Endosc 2023; 15(6): 440-446
- URL: https://www.wjgnet.com/1948-5190/full/v15/i6/440.htm
- DOI: https://dx.doi.org/10.4253/wjge.v15.i6.440